IP Library Granted Patent US 7,932,250
Granted Patent B2
US 7,932,250 · App. 11/630,757 · Granted Apr 26, 2011

Thienopyrazole derivative having PDE7 inhibitory activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,250
App. No.
11/630,757
Granted
Apr 26, 2011
Kind
B2
Abstract

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: —CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].

Claims (98)

1. Thienopyrazole compounds represented by the following formula (I):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted, or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

R 5 and R 6 are, same or different from each other, a hydrogen atom; C 1 -C 6 alkyl group which may be substituted by a halogen atom, substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted cycloalkyl group, a group —NR 7 COR 8 , —COR 8 , —NR 9 R 10 ; substituted or unsubstituted cycloalkyl group; substituted or unsubstituted heterocycloalkyl group; substituted or unsubstituted aryl group; substituted or unsubstituted heteroaryl group; or substituted or unsubstituted heterocycloalkyl group in which the ring is formed together with the nitrogen atom binding R 5 and R 6 ;

R 7 is a hydrogen atom, or substituted or unsubstituted C 1 -C 3 alkyl group;

R 8 is a substituted or unsubstituted heterocycloalkyl group, or a group —OH, —OR 7 or —NR 9 R 10 ;

R 9 and R 10 are, same or different from each other, a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, substituted or unsubstituted heterocycloalkyl group; substituted or unsubstituted acyl group; a group —SO 2 R 7 , or substituted or unsubstituted heterocycloalkyl group in which the ring is formed together with the nitrogen atom binding R 5 and R 6 or pharmaceutically acceptable salts or solvates thereof.

2. The compound according to claim 1 , wherein R 1 is a substituted or unsubstituted cycloalkyl group.

3. The compound according to claim 1 , wherein R 1 is a substituted or unsubstituted heterocycloalkyl group.

4. The compound according to claim 1 , wherein R 1 is a substituted or unsubstituted cyclohexyl group.

5. The compound according to claim 1 , wherein R 1 is a substituted or unsubstituted tetrahydropyranyl group.

6. The compound according to claim 1 , wherein R 2 is a methyl group.

7. The compound according to claim 1 , wherein R 3 is a hydrogen atom.

8. The compound according to claim 1 , wherein R 4 is —CONR 5 R 6 .

9. The compound according to claim 8 , wherein any one of R 5 and R 6 is a hydrogen atom.

10. The compound according to claim 8 , wherein any one of R 5 and R 6 is a substituted or unsubstituted cycloalkyl group.

11. The compound according to claim 8 , wherein any one of R 5 and R 6 is a cycloalkyl group which is substituted by a heterocycloalkyl group which may be substituted.

12. The compound according to claim 8 , wherein any one of R 5 and R 6 is an aryl group which may be substituted.

13. The compound according to claim 8 , wherein any one of R 5 and R 6 is an aryl group which is substituted by a heterocycloalkyl group which may be substituted.

14. The compound according to claim 8 , wherein any one of R 5 and R 6 is a substituted or unsubstituted heteroaryl group.

15. A pharmaceutical composition containing a compound according to claim 1 , or a pharmaceutical acceptable salt thereof, as an active ingredient and a pharmaceutically acceptable diluent or exipient.

16. A method of inhibiting PDE 7 in a subject in need thereof comprising administering a compound according to claim 1 , or a pharmaceutical acceptable salt thereof, to the subject to inhibit PDE 7.

17. A method for preparing the thienopyrazole compounds represented by the formula (I):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom,

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

comprising chlorinating the pyrazole-5-one derivative represented by the formula (VI):

wherein

R 1 is substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group; and then, undergoing an electrophilic substitution reaction of the resulting compound without separation to give the pyrazole derivative of the formula (IV):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group,

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

then, reacting the resulting pyrazole derivative of formula (IV) with the compound of the formula (III) in the presence of base:

wherein

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group or a group —CONR 5 R 6 or —CO 2 R 7 ,

to give the compound of the formula (II):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

and then, treating the resulting compound of formula (II) with base to give the thienopyrazole compound of the formula (I).

18. A method for preparing the thienopyrazole compounds represented by the formula (I):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

comprising undergoing an electrophilic substitution reaction of the chloropyrazole derivative of the formula (V):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

to give the pyrazole derivative of the formula (IV):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 3 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

then, reacting the resulting pyrazole derivative of formula (IV) with the compound of the formula (III) in the presence of base:

wherein

R 4 is a substituted or unsubstituted aryl group substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

to give the compound of the formula (II):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

and then, treating the resulting compound of formula (II) with base to give the thienopyrazole compound of the formula (I).

19. A method for preparing the thienopyrazole compounds represented by the formula (I):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

comprising reacting the pyrazole derivative of formula (IV):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

with the compound of the formula (III) in the presence of base:

wherein

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

to give the compound of the formula (II):

wherein

R 1 is a substituted or unsubstituted C 3 -C 8 alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;

R 2 is a hydrogen atom or substituted or unsubstituted C 1 -C 3 alkyl group;

R 3 is a hydrogen atom, substituted or unsubstituted C 1 -C 3 alkyl group, or a halogen atom;

R 4 is a substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, or a group —CONR 5 R 6 or —CO 2 R 7 ;

and then, treating the resulting compound of formula (II) with base to give the thienopyrazole compound of the formula (I).

20. The method for preparing thienopyrazole compound according to claim 19 ,

wherein the conversion of the compound of formula (IV) to the compound of formula (I) is carried out in one pot synthesis without separation of the compound of the formula (II).

21. The method according to claim 17 , wherein the group R 3 is a hydrogen atom.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Nov 25, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: OMEROS CORPORATION
Reel/Frame 073705/0970 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE BOX TITLED"THIS DOCUMENT SERVES AS AN OATH/DECLARATION (37 CFR 1.63)" WAS ERRONEOUSLY CHECKED AND THIS BOX SHOULD NOT HAVE BEEN CHECKED, PREVIOUSLY RECORDED AT REEL: 67607 FRAME: 108. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Dec 11, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 069715/0719 →
SECURITY INTEREST Recorded Jun 3, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 067607/0108 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2018
From: CRG SERVICING LLC
To: OMEROS CORPORATION
Reel/Frame 047573/0577 →
SECURITY INTEREST Recorded Nov 7, 2016
From: OMEROS CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040575/0110 →
MERGER Recorded Aug 5, 2010
From: ASUBIO PHARMA CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 024793/0258 →